Article
ASCO GU: AstraZeneca, Merck's Lynparza one-ups J&J's Zejula with prostate cancer win regardless of gene mutations
Rating:
0.0
Views:
57
Likes:
1
Library:
1
AstraZeneca and Merck & Co.'s Lynparza may have a narrower label than GlaxoSmithKline's rival drug Zejula in ovarian cancer, but in prostate cancer, the situation could flip.< | AstraZeneca and Merck & Co.'s Lynparza may have a narrower label than GlaxoSmithKline's rival drug Zejula in ovarian cancer, but in prostate cancer, the situation could flip.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value